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Abstract
Background—Use of nonsteroidal anti-inflammatory drugs (NSAID) has been associated with a
decrease in breast cancer risk, but it is unknown if they also reduce mammographic density, a
strong intermediate marker of breast cancer risk.
Methods—We investigated NSAID use and mammographic density in 29,284 postmenopausal
women who had two screening mammograms at Group Health in Seattle. We used pharmacy
records to classify women as NSAID nonusers, continuers, initiators, or discontinuers based on
use between the two mammograms and nine separate prescription and nonprescription NSAID
classes. Using unordered polytomous logistic regression methods, we modeled the odds ratio (OR)
of staying not dense, decreasing density, or increasing density relative to remaining dense based
on Breast Imaging Reporting Data System classification of density.
Results—There was no association with density change from initiation or continuation of
NSAIDs. However, both initiators and continuers of any NSAIDs were more likely to stay not
dense than stay dense [OR, 1.12; 95% confidence interval (95% CI), 1.04-1.20; OR, 1.25; 95% CI,
1.05-1.49, respectively]. This association with staying not dense for initiators and continuers of
any NSAID use was observed primarily among women ages <65 years at first mammogram (OR,
1.24; 95% CI, 1.12-1.36; OR, 1.48; 95% CI, 1.14-1.93, respectively).
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Conclusions—Initiation of NSAID use did not reduce mammographic density over the short
term. Continuers of NSAID use were more likely to stay not dense compared with nonusers,
suggesting that it is plausible that longer-term use of NSAIDs may be needed to reduce density.
Introduction
Nonsteroidal anti-inflammatory drug (NSAID) use has been associated with a reduction in
many cancers (1, 2). NSAIDs inhibit cyclooxygenase, which catalyzes the synthesis of
prostaglandins; prostaglandin inhibition has reduced tumor formation in animal models (3,
4). Many observational epidemiologic studies of aspirin and other NSAIDs and breast
cancer risk have supported a reduction in risk usually in the range of 20% to 40% (1, 5-23),
although several prospective observational studies (24-27) as well as prevention trials, like
the Women’s Health Study, have not (28). The inconsistencies across studies may be
explained by real differences in dose and duration of NSAIDs across the studies and/or by
reporting biases and residual confounding likely to be present in observational settings.
Despite the large, and growing, literature on NSAIDs and breast cancer risk, little is known
regarding the relation between NSAID use and mammographic breast density.
Mammographic density, which reflects the amount of epithelial and stromal tissue compared
with total breast tissue, is one of the strongest indicators of future breast cancer risk (29-33).
Recently, a large study supported that decreases in mammographic density over time are
associated with decreases in breast cancer risk (34). Many breast cancer risk factors,
including hormone replacement use, parity, and alcohol use, have also been associated with
mammographic density (35-44). NSAIDs, through cyclooxygenase inhibition, may affect
estrogen biosynthesis. Prostaglandins, like PGE2, have been shown to increase aromatase
gene expression and thereby estrogen production in cultured cells (45) as well as stimulate
progesterone synthesis (46). Increase in both progesterone and estrogen may increase
mammographic density (47); thus, inhibition of prostaglandin synthesis through NSAIDs
may reduce breast density.
We undertook a study to investigate whether NSAID use was associated with changes in
mammographic density. We did so by using prospectively collected data from the Group
Health pharmacy records of 29,284 women who had mammographic density readings from
at least two separate routine mammography screening exams. All mammographic density
assessments were conducted blinded to exposure information, and all exposure information
was from pharmacy records and not based on individual self-reports.
Materials and Methods
Study Population
Group Health, an integrated group practice in western Washington State with ~550,000
members, has a population-based Breast Cancer Screening Program that women are invited
to join at their first mammogram (48, 49). Self-reported demographic and breast cancer risk
factor information are gathered by a self-administered questionnaire from women when they
join the Breast Cancer Screening Program and at each screening mammogram (49).
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We identified 30,834 women who had two routine screening mammograms within 9 to 28
months of each other anytime between 1996 and 2006; if the same women had multiple
exams during these years, we selected two exams closest to 18 months apart. We excluded
women who reported ever using raloxifene or tamoxifen, women with a history of breast
cancer either before or detected at the first screening mammogram, or women who had
breast augmentation or reduction reported at either exam. No exclusion criteria were made
by race or age but we did exclude women who were premenopausal at either mammogram
screening. We further excluded women who had no information on age at menopause or
type of menopause or information on other covariates, including body size and hormone
replacement use. A total of 29,284 met these criteria and were available for analysis. The
study was approved by the institutional review boards of Group Health and Columbia
University. A waiver of consent for all women entering the Group Health breast screening
clinic to allow for linkage of data and a waiver for Health Insurance Portability and
Accountability Act authorization from the institutional review board were obtained.
Categorization of NSAID Use
We searched automated pharmacy records to collect information on aspirin and other
NSAID dispensings. We classified aspirin and NSAID use into the following nine
categories: aspirin, proprionic acid, indole/indene acids, anthranillic acids, enolic acids,
heteroaryl acetic acid, alkones, and two classes of cyclooxygenase inhibitors (Coxib1 and
Coxib2). We further categorized NSAID use by nonprescription, prescription, and any
NSAID use. Nonprescription NSAID use included aspirin and proprionic acid. Prescription
NSAID use included indole/indene acids, anthranillic acids, enolic acids, heteroaryl acetic
acid, alkones, and cyclooxygenase inhibitors. Any NSAID use included use of any of the
nine classes of NSAIDs.
For each NSAID type, we first described use before the date of the first mammogram by
duration of use (total days supplied) in the 10 years before the first mammogram. Duration
of use between mammograms was recorded by the total days supply for all dispensings
between the two mammograms. The intended duration of each dispensing (and the run out
date) was established using automated data on number of pills dispensed. A new run-out
date was set with each successive dispensing rather than using cumulative number of pills
from all dispensings (50). We used the dispensing information to categorize women as
initiators, discontinuers, continued users, or never users of NSAIDs at the two mammograms
using information on dispensings before the first mammogram and for the time between
both mammograms following groups. Initiators were women who did not use the NSAID at
the time of the first mammogram but started before their second mammogram and must
have had a dispensing within 6 months of the second mammogram. Continuers were women
who had pharmacy dispensings for the entire period between the two mammograms.
Discontinuers were women who were dispensed a given class of NSAIDs at the first
mammogram but had no dispensings within 6 months before the second mammogram.
Nonusers did not have any pharmacy fills for a given class of NSAID within the 6 months
before the first and the second mammograms. Individuals who may have initiated one type
of NSAID while discontinuing another or continued one type of NSAID while initiating or
discontinuing another were defined as “mixed” type and treated as a separate category.
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Classification of Mammographic Density
All mammograms completed at Group Health received Breast Imaging Reporting Data
System (BI-RADS; ref. 51) breast density measures as part of the clinical interpretation (1,
entirely fat; 2, scattered fibroglandular; 3, heterogeneously dense; 4, extremely dense). The
reliability of the BI-RADS assessment has ranged from ~0.6 to 0.8 (52-54). The BI-RADS
measure has been shown in many studies to be associated with breast cancer risk, and even
more recently, changes in BI-RADS categories have been associated with changes in breast
cancer risk (34). A description of the reliability and validity of the measure has been added
to the methods.
We categorized change in density by comparing responses for the BI-RADS score for the
two time points. We created four categories: stayed nondense (women who remain in BI-
RADS category 1 or 2 at both exams), stayed dense (women who remain in category 3 or 4
at both exams), increased density (women who increase from category 2 to 3), and
decreased density (women who decrease from category 3 to 2; ref. 47). In addition to these
primary classifications, we also examined the association between NSAID use and one
category change through both continuous and categorical measures (see statistical analysis
section below).
Other Risk Factor Data
The Breast Cancer Screening Program questionnaire collects data on established breast
cancer risk factors, such as age at menarche, age at menopause, type of menopause, oral
contraceptive use, hormone replacement therapy (HRT) use, type and duration of hormone
therapy used, age at first birth, parity, benign breast biopsy history, number of previous
breast biopsies, race, body mass index (BMI), and date of last mammogram. Self-report
information is updated at each mammogram. Our study was designed so each woman’s
density was compared between two time points. As such, confounders, either measured with
error or unmeasured, which do not change with time, will not explain density differences
over time. Therefore, in addition to age at the first mammogram, we only included
covariates that could have changed between two exams in the multivariable models:
hormone therapy, BMI, and time between exams.
Statistical Analysis
We compared characteristics of women by category of any NSAID use (nonuser, initiator,
discontinuer, continuer, or mixed type) by age, race, ethnicity, BMI, breast density at first
and second mammograms, HRT at first and second mammograms, and days between exams.
We then compared the distribution of women by NSAID user type (nonuser, initiator,
discontinuer, continuer, or mixed type) by their BI-RADS category on both exams. In
addition to univariate statistics, we examined the association between NSAID use and
mammographic density by using ordered polytomous logistic regression (55). We modeled
three logits compared for women who increased, decreased, and remained nondense and
compared them with the reference group of women who remained dense. We considered
women who remained dense as the reference group to examine the hypothesis that women
who initiated NSAIDS would decrease density relative to those who remained dense.
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We examined any NSAID, prescription NSAID, or nonprescription NSAID based on status
as nonuser, initiator, discontinuer, continuer, or mixed type user. The exposure reference
group was the nonuser category for all classes of NSAIDs. In addition to the age-adjusted
models, we examined the following variables that changed between the first and the second
mammograms to test whether they confounded the relation between density and NSAID use:
HRT, BMI, and time between exams. HRT use was categorized relative to nonusers as
initiators, discontinuers, or continuers based on use at the two mammography exams. BMI
was examined both as a continuous difference and as a categorical difference (<25, >25)
between the two exams. Time between exams was represented as a continuous variable
measured in days. In addition to these a priori confounders that were based on risk factors
that change since the baseline mammogram and are known to effect density, we did
supplemental analyses that adjusted for other known risk factors for breast cancer, including
family history of breast cancer, parity, age at first birth, and age at menarche. These
variables and the a priori confounders were only included in the final models if they altered
the variable estimates on NSAID use by >10%.
We also examined whether the association between any NSAID use and change in breast
density was modified by age at first mammography (≤65, >65), HRT use (ever/never), time
between mammograms (≤2, >2 years), and BMI at first mammogram (≤25, >25). In addition
to the primary models that categorized density change as described above, we did secondary
analysis examining whether our inferences changed when only examining a one-unit change
in density through repeated binary logistic models.
Results
Of the 29,284 women, 89% were White, 7% were African American, and 4% were other
race. Table 1 summarizes the descriptive statistics by category of any NSAID use (nonusers,
initiator, discontinuer, continuer, and mixed). Nonusers of NSAIDs were more likely to be
younger, have lower BMI, be never users of HRT, and have dense breast tissue (BI-RADS
category 3 or 4). Age at menarche, family history of breast cancer, and age at first birth were
similar between nonusers and initiators of NSAIDs; however, mixed users of NSAIDS were
more likely to differ from nonusers on these factors. The average time between exams was
similar between initiators and nonusers of NSAIDs but was lower for continuers and users
of mixed type. Overall, the range for the time between exams was 247 to 881 days.
Table 2 presents a cross-tabulation of breast density at the two exams according to category
of any NSAID use. In general, the pattern of density changes was similar across the four
categories of NSAID use. For example, 24.8% of NSAID initiators who had
heterogeneously dense breasts (category 3 BI-RADS) at the first mammogram decreased
density to scattered fibroglandular (category 2 BI-RADS) at the second mammogram
compared with 22.1% of nonusers, 28% of discontinuers, 24.3% of continuers, and 26.6% of
mixed use category.
Table 3 presents the age-adjusted and multivariable odds ratio (OR)–adjusted findings for all
categories of use (initiator, discontinuer, continuer, and mixed) by any NSAID use and
separately by nonprescription NSAIDs (aspirin and proprionic acid) and prescription
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NSAIDs (the other seven classes). Initiators and continuers of any NSAID were more likely
to stay not dense than stay dense [multivariable OR, 1.12; 95% confidence interval (95%
CI), 1.04-1.20; multivariable OR, 1.25; 95% CI, 1.05-1.49, respectively]. Point estimates
were the same for initiators of nonprescription and prescription NSAIDs for staying not
dense compared with staying dense (multivariable OR, 1.11; 95% CI, 1.03-1.20;
multivariable OR, 1.11; 95% CI, 0.97-1.26, respectively). Discontinuers of nonprescription
NSAIDs were more likely to decrease density compared with nonusers (OR, 1.40; 95% CI,
1.10-1.79) compared with staying dense. There was no association with density change from
discontinuation of prescription NSAIDs nor was there an association between continuation
of NSAIDs (either prescription or nonprescription) and density change (increase or
decrease). However, continuers of nonprescription NSAIDs were more likely to stay not
dense compared with those who stayed dense (OR, 1.40; 95% CI, 1.13-1.72). Users in the
“mixed” type category of NSAID use included individuals who may have initiated,
discontinued, or continued NSAID use within the same period. Mixed users of
nonprescription NSAIDs were more likely to increase density, whereas mixed users of
prescription NSAIDS were less likely to increase density (OR, 1.64; 95% CI, 1.08-2.48; OR,
0.58; 95% CI, 0.35-0.96, respectively).
We further examined whether the association between any NSAID use and change in
mammographic density was modified by age at first mammogram (<65, >65), HRT use
(ever, never), time between mammograms (<2, >2 years), and BMI at first mammogram
(<25, >25). Only age at first mammogram significantly modified the association (test for
multiplicative interaction P = 0.02). These findings are presented in Table 4. The overall
finding that initiators and continuers of any NSAIDs were more likely to stay not dense
compared with staying dense reported in Table 4 was limited to women ages <65 years (OR,
1.24; 95% CI, 1.12-1.36; OR, 1.48; 95% CI, 1.14-1.93 for women ages <65 years compared
with OR, 1.02; 95% CI, 0.92-1.14; OR, 1.18; 95% CI, 0.93-1.48 for women ages ≥65 years).
In addition to these primary analyses, we did secondary analyses to evaluate whether a one-
unit change in BI-RADS within the category of stayed not dense (category 1 and 2) and
stayed dense (category 3 and 4) altered our conclusions. There was no association between
each category of any NSAID use (initiation, discontinuation, continuation, and mixed type)
and increasing density by a one-unit change in BI-RADS (category 1-2 compared with
staying at category 1; 2, to 3 compared with staying at category 2; 3, to 4 compared with
staying at category 3; data not shown). There was also no association between each category
of any NSAID use and decreasing density by a one-unit change in BI-RADS (category 4 to
3 compared with staying at category 4; 3, to 2 compared with staying at category 3; and
category 2 to 1 compared with staying at category 2; data not shown). We further compared
individuals who remained at category 2 for both exams with those individuals who remained
at category 3 for both exams. Initiation of any NSAID use and continuation of any NSAID
use was positively associated with remaining at category 2 compared with those who
remained at category 3 (multivariable OR, 1.12; 95% CI, 1.03–1.22; multivariable OR, 1.22;
95% CI, 0.98-1.49, respectively). Thus, if our analyses focused on cross-sectional measures
rather than change in density, NSAID use would be associated with overall lower density.
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Discussion
Overall, we did not observe a reduction in mammographic breast density from initiation of
NSAIDs by class or type of NSAID. Nor did we observe an increase in density from
discontinuation of use. We did observe that initiation or continuation of any NSAID use, and
nonprescription aspirin in particular, was associated with a 11% to 40% increase chance of
staying not dense compared with staying dense. These findings were primarily observed in
women ages <65 years.
We investigated density change using the BI-RADS classification where a change in
category represents a large change in mammographic density in the range of 25%. Initiation
of HRT use has been associated with an increase in breast density using the BI-RADS
classification system (47). In our own data, HRT initiation was positively associated with an
increase in density relative to staying dense using the categories we described (multivariable
OR, 1.59; 95% CI, 1.22-2.06). The increase in mammographic breast density from HRT use
has largely been used to argue that estrogen and progesterone levels increase breast density,
although direct measures of circulating levels of estradiol have not been associated with
higher density and may operate independently of breast density in postmenopausal women
(56, 57). Based on the HRT evidence, we hypothesized that NSAIDs may reduce breast
density through inhibition of prostaglandins, like PGE2, which have been shown to increase
aromatase gene expression and stimulate progesterone synthesis (46).
To date, change in BI-RADS category, but not smaller within-category changes in density,
has been associated with change in breast cancer risk (34). Thus, it is important to continue
to understand factors that might relate to large changes in breast density over time. It is
entirely plausible that chemoprevention agents such as NSAIDs will result in a within-
category change in density rather than a whole category change; however, smaller within-
category differences in density have not yet been shown to be related to breast cancer.
Another explanation for the lack of overall association between initiation of NSAID use and
density change is the relatively short period covered by this observational study. On average,
the two mammograms were from visits just under 2 years apart. Longer-term use of NSAIDs
or longer time between mammograms may be needed to observe a more modest effect.
Indeed, both continuers and initiators were more likely to stay not dense, but the estimate
was slightly higher for continuers, suggesting that longer-term NSAID use may be needed to
remain not dense or lower density. We did stratify by time between mammograms and did
not observe any large associations for those who had a longer time between mammograms
(>2 years) and those who had a shorter time between mammograms (<2 years).
The only other study that has been published examining NSAID use and mammographic
density used data from 218 premenopausal women and a separate case-control study of
1,274 women (58). This study by Maskarinec et al. evaluated a single measure of
mammographic density using a continuous scale and relied on self-report of NSAIDs. This
study did not find any overall association between NSAID use and mammographic density.
Among postmenopausal women, long-term NSAID use (>11 years) was associated with a
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higher mammographic density. Our study relied on BI-RADS classification and assessment
of mammographic change and did not rely on self-reported NSAIDs.
There are many strengths of our large study using data from over 29,000 women. The
overall power of the study was extremely high for most comparisons. For example, we had
80% power to detect associations as small as 1.17 between any NSAID and decreasing
density. We had 80% power to detect associations as small as 1.18 for nonprescription and
1.3 for prescription NSAIDs. Power for the specific types of prescription NSAIDs was
lower; thus, for the primary analyses, we focused on overall, prescription, and
nonprescription NSAID rather than specific class. All mammograms were interpreted
blinded to any information on exposure to NSAIDs. All exposure information was collected
from automated pharmacy records and did rely on individual self-report or recall. It is
possible, however, that the pharmacy dispensings were not ingested, and it is likely that
nonprescription NSAIDs were purchased outside of Group Health. These misclassification
errors likely resulted in a nondifferential measurement error toward the null, which could
contribute to our overall lack of association between NSAIDs and density change. The
nondifferential measurement error cannot explain the positive association between NSAID
use and remaining not dense relative to remaining dense.
Another important strength of our study is that we assessed change in density within
individual women. Such a design means that confounders, either measured with error or
unmeasured, which do not change with time, cannot account for differences in density. This
is important, as regular NSAID users are likely to differ from non-NSAID users in a number
of important ways. For example, in our own study, we observed that nonusers of NSAIDs
were more likely to be younger, have lower BMI, and never use HRT compared with
NSAID users. We were also able to assess factors that may change with time that could have
confounded the relation, such as initiation of HRT use or change in BMI. Removing residual
confounding in the NSAID and breast cancer risk association is especially important as the
only randomized trial of breast cancer risk reported to date did not observe a reduction in
risk from low-dose aspirin (28). As a result, some have argued that the consistent association
reported in the observational studies, many of which were case-control designs, might be
explained by residual confounding and reporting bias. It is true that many of the
observational studies of breast cancer risk relied on self-reporting of NSAID use. However,
of four studies that used pharmacy or medical records, three reported an inverse association
between NSAID use and breast cancer risk (12, 20, 22, 23), suggesting that the inverse
association is not limited to studies with self-reported data. Although dose is available in the
Group Health automated pharmacy dispensing data, we were less confident that a dose-
specific analysis would provide any additional information largely because many of these
drugs are over the counter and we had no information on the actual dose women chose to
take.
Overall, our study using records from over 29,000 women does not suggest that NSAID
initiation over a relatively short period (average, <2 years) can lead to a change in category
of mammographic density. We were unable to rule out smaller changes in density from
NSAID use or changes in density from longer durations of NSAID use. Both continuers and
initiators of NSAIDs were more likely to stay not dense, suggesting that either long-term use
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is needed to remain not dense (continuers) or initiation may be correlated with other factors
associated with lower density. Our study also reveals the importance of evaluating multiple
measures of density over time as a single cross-sectional measure would support the
association that ever NSAID use is associated with lower density. Multiple measures reveal
a more complex association. Focusing on factors that lead to large changes in density may
ultimately prove the greatest benefit for understanding and preventing breast cancer.
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Table 1
Characteristics of postmenopausal women by NSAID use, Group Health, 1996-2006
Characteristics Nonuser
(n = 20,653), %
Initiator
(n = 5,978), %
Discontinuer
(n = 1,156), %
Continuer
(n = 838), %
Mixed
(n = 659), % P 
*
% Women in each category 70.5 20.4 4.0 2.9 2.2
Age at first
 mammogram (y)
 ≤49 8.5 7.1 8.1 4.4 6.8 <0.0001
 50-59 38.3 30.4 33.3 24.4 26.6
 60-69 28.9 27.9 29.0 27.9 28.1
 70-79 18.9 26.9 23.6 32.7 30.2
 80-98 5.4 7.7 6.0 10.6 8.3
Age at second mammogram (y)
 ≤49 5.3 4.4 6.0 2.8 4.4 <0.0001
 50-59 35.3 27.8 30.2 22.1 25.0
 60-69 30.5 28.4 29.5 25.9 26.4
 70-79 21.4 28.2 25.2 34.0 31.9
 80-100 7.5 11.2 9.1 15.2 12.3
Race
 White 89.1 89.3 88.1 90.1 89.8 0.056
 Black 6.9 6.9 7.0 5.6 5.3
 American Indian/Alaska Native 2.1 2.3 3.0 2.9 3.3
 Asian/Hawaiian/Pacific Islander 1.5 1.2 1.6 1.2 0.8
 Unknown 0.4 0.3 0.3 0.2 0.8
Ethnicity
 Hispanic 3.3 3.9 4.2 3.1 4.2 0.15
 Not Hispanic 96.3 95.7 95.2 96.2 95.0
 Unknown 0.4 0.4 0.6 0.7 0.8
BMI (at first mammogram)
 <25 42.7 34.3 36.0 29.6 25.5 <0.0001
 25-30 30.5 32.2 30.5 31.6 30.3
 >30 22.8 29.0 29.8 34.4 38.1
 Unknown 4.0 4.5 3.6 4.4 6.1
BI-RADS category at
 first mammogram
 Entirely fat (1) 9.3 11.2 9.2 13.8 10.6 <0.0001
 Scattered fibroglandular (2) 43.8 47.6 47.2 50.1 51.0
 Heterogeneously dense (3) 39.5 35.5 38.0 31.9 33.1
 Extremely dense (4) 7.4 5.7 5.6 4.2 5.3
BI-RADS category at
 second mammogram
 Entirely fat (1) 7.6 9.5 7.4 10.7 11.4 <0.0001
 Scattered fibroglandular (2) 43.1 46.9 48.9 49.6 46.4
 Heterogeneously dense (3) 42.5 38.4 39.5 35.6 37.5
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Characteristics Nonuser
(n = 20,653), %
Initiator
(n = 5,978), %
Discontinuer
(n = 1,156), %
Continuer
(n = 838), %
Mixed
(n = 659), % P 
*
 Extremely dense (4) 6.8 5.2 4.2 4.1 4.7
HRT use
 Nonuser 26.6 23.1 23.3 21.2 19.6 <0.0001
 Initiator 1.9 2.3 1.5 2.1 1.5
 Discontinuer 31.0 30.8 32.4 31.2 30.8
 Continuer 40.3 43.6 42.6 45.0 47.5
 Unknown 0.2 0.2 0.2 0.5 0.6
Days between exams
 Mean 634.9 632.3 639.1 613.3 619.3 <0.0001
 SD 130.5 125.7 128.5 137.8 135.7
 Median 676 670 674 661 671
Age at menarche (y)
 Never 0.3 0.4 0.4 0.7 0.5 <0.0001
 <11 5.6 6.1 7.0 8.9 6.4
 11-14 72.2 73.5 70.0 73.4 77.2
 ≥15 10.5 10.8 12.0 9.2 8.0
 Unknown 11.4 9.2 10.6 7.8 7.9
Family history
 No family history 58.7 60.7 57.5 55.5 57.4 0.0004
 First-degree relative 17.8 17.7 19.9 22.1 19.9
 Second-degree relative 14.3 14.1 13.8 12.8 13.8
 Unknown 9.2 7.5 8.8 9.6 8.9
Age at first birth (y)
 Not parous 15.1 13.1 13.4 10.9 12.8 <0.0001
 ≤19 16.6 20.1 19.8 21.7 21.8
 20-24 37.7 37.8 39.4 39.3 41.7
 25-29 19.1 18.2 17.6 18.4 16.7
 ≥30 9.5 9.0 7.5 7.0 5.5
 Unknown 2.0 1.8 2.3 2.7 1.5
*
P values calculated from χ2 tests of independence between NSAID use category and each calculated for categorical characteristics and from
ANOVA for continuous variables.
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Table 2
Cross-tabulation of women in each BI-RADS density category at first mammogram
compared with value at second mammogram (row percent); Group Health, 1996-2006
Any NSAID use and BI-RADS density
category at first mammogram
BI-RADS density category at second mammogram
Entirely
fat, n (%)
Scattered
fibroglandular, n (%)
Heterogeneously
dense, n (%)
Extremely
dense, n (%)
Nonuser
 Entirely fat 869 (45.4) 972 (50.8) 67 (3.5) 6 (0.3)
 Scattered fibroglandular 676 (7.5) 6,077 (67.2) 2,238 (24.7) 55 (0.6)
 Heterogeneously dense 35 (0.4) 1,800 (22.1) 5,721 (70.0) 614 (7.5)
 Extremely dense 2 (0.1) 45 (3.0) 747 (49.0) 729 (47.9)
Initiator
 Entirely fat 314 (46.8) 332 (49.5) 24 (3.6) <5 (0.1)
 Scattered fibroglandular 240 (8.4) 1,943 (68.3) 646 (22.7) 16 (0.6)
 Heterogeneously dense 12 (0.5) 526 (24.8) 1,439 (67.8) 146 (6.9)
 Extremely dense 0 (0.0) <5 (0.9) 185 (54.6) 151 (44.5)
Discontinuer
 Entirely fat 49 (46.2) 54 (51.0) < 5 (2.8) 0 (0.0)
 Scattered fibroglandular 37 (6.8) 386 (70.7) 119 (21.8) <5 (0.7)
 Heterogeneously dense 0 (0.0) 123 (28.0) 295 (67.2) 21 (4.8)
 Extremely dense 0 (0.0) <5 (3.1) 39 (60.0) 24 (36.9)
Continuer
 Entirely fat 51 (44.0) 63 (54.3) <5 (1.7) 0 (0.0)
 Scattered fibroglandular 38 (9.1) 287 (68.3) 95 (22.6) 0 (0.0)
 Heterogeneously dense <5 (0.4) 65 (24.3) 183 (68.6) 18 (6.7)
 Extremely dense 0 (0.0) <5 (2.9) 18 (51.4) 16 (45.7)
Mixed
 Entirely fat 41 (58.6) 29 (41.4) 0 (0.0) 0 (0.0)
 Scattered fibroglandular 33 (9.8) 219 (65.2) 83 (24.7) <5 (0.3)
 Heterogeneously dense <5 (0.5) 58 (26.6) 149 (68.3) 10 (4.6)
 Extremely dense 0 (0.0) 0 (0.0) 15 (42.9) 20 (57.1)
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Table 4
Association between any NSAID use and change in mammographic density between two
screening mammograms* stratified by age at first mammogram, Group Health,
1996-2006
<65 y ≥65 y
Increase vs stay
dense, OR
(95% CI)*
Decrease vs stay
dense, OR
(95% CI)*
Stay not dense vs
stay
dense, OR
(95% CI)*
Increase vs stay
dense, OR
(95% CI)*
Decrease vs stay
dense, OR
(95% CI)*
Stay not dense vs
stay
dense, OR
(95% CI)*
Nonuser 1.00 1.00 1.00 1.00 1.00 1.00
Initiator 1.04 (0.90-1.19) 1.12 (0.96-1.30) 1.24 (1.12-1.36) 1.05 (0.90-1.22) 1.06 (0.89-1.25) 1.02 (0.92-1.14)
Discontinuer 0.93 (0.70-1.23) 1.09 (0.82-1.45) 1.00 (0.83-1.22) 1.14 (0.82-1.59) 1.51 (1.08-2.11) 1.22 (0.97-1.54)
Continuer 1.23 (0.85-1.80) 1.07 (0.69-1.65) 1.48 (1.14-1.93) 1.09 (0.78-1.51) 1.01 (0.69-1.48) 1.18 (0.93-1.48)
Mixed 1.30 (0.88-1.92) 1.38 (0.91-2.09) 1.29 (0.97-1.71) 0.96 (0.65-1.41) 0.75 (0.46-1.21) 0.99 (0.75-1.30)
*Adjusted for BMI at first mammogram, HRT use, and time between the two mammograms.
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